<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114328">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01935167</url>
  </required_header>
  <id_info>
    <org_study_id>DW1029M</org_study_id>
    <nct_id>NCT01935167</nct_id>
  </id_info>
  <brief_title>To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy</brief_title>
  <official_title>A Phase Ⅱ, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ⅱ, prospective, 24 weeks, double-blind, placebo-controlled, randomized, multi-center
      clinical trial for the evaluation of the efficacy and safety of DW1029M on microalbuminuria
      in Patients With Diabetic Nephropathy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>log ACR</measure>
    <time_frame>at 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>DW1029M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DW1029M 600mg, bid, 24weeks DW1029M 1200mg, bid, 24weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 600mg/1200mg, bid, 24weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW1029M</intervention_name>
    <description>DW1029M 600mg/1200mg</description>
    <arm_group_label>DW1029M</arm_group_label>
    <other_name>DW1029M 600mg</other_name>
    <other_name>DW1029M 1200mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has confirmed diabetic mellitus prior to 6years

          -  Has confirmed microalbuminuria 30 ~ 299㎍/㎎creatinine prior to 5months one time and
             microalbuminuria 30 ~ 299㎍/㎎creatinine during screening period

          -  BP ≤ 150 / 90 mmHg

          -  eGFR ≥ 30 ml/min/1.73m2

          -  HbA1c ≤ 9%

          -  LDL-C ≤ 130mg/dl

        Exclusion Criteria:

          -  kidney or liver disease as follows i.Serum Creatinine &gt; 2.0mg/dl ii.ALT 또는 AST &gt; 2 x
             ULN iii.Total Bilirubin &gt; 2 x ULN

          -  Organic gastrointestinal disorder or Chronic gastroenterologic disorders prior to 6
             months as follows [NOTE] Active Crohn's disease, Active ulcerative colitis, Chronic
             peptic ulcer disease, etc.

          -  cardiovascular disease prior to 3 months as follows [NOTE] Unstable angina pectoris,
             Myocardial infarction, Coronary artery bypass surgery, Percutaneous Transluminal
             Coronary Angioplasty, transient ischemic attack, cerebrovascular accident etc.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MoonKyu Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keunhee Kim, manager</last_name>
    <phone>82-2-2021-9554</phone>
    <email>keunhee.kim@dong-wha.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>DongWha Pharm</name>
      <address>
        <city>Seoul</city>
        <zip>100-130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keunhee Kim, manager</last_name>
      <phone>82-2-2021-9554</phone>
      <email>keunhee.kim@dong-wha.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>September 3, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
